Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
BMJ Open Respir Res ; 11(1)2024 Aug 22.
Artigo em Inglês | MEDLINE | ID: mdl-39179271

RESUMO

BACKGROUND: Cancer is one of the leading causes of death worldwide, and cardiopulmonary comorbidities may further adversely affect cancer prognosis. We recently described lung cancer-associated pulmonary hypertension (PH) as a new form of PH and comorbidity of lung cancer. While patients with lung cancer with PH had significantly reduced overall survival compared with patients without PH, the prevalence and impact of PH in other cancers remain unclear. METHODS: In this retrospective, observational cohort study, we analysed the prevalence and impact of PH on clinical outcomes in 1184 patients with solid tumours other than lung cancer, that is, colorectal, head and neck, urological, breast or central nervous system tumours, using surrogate markers for PH determined by CT. RESULTS: PH prevalence in this cohort was 10.98%. A Cox proportional hazard model revealed a significant reduction in the median survival time of patients with cancer with PH (837 vs 2074 days; p<0.001). However, there was no correlation between pulmonary metastases and PH. A subgroup analysis showed that PH was linked to decreased lung and cardiac function. Additionally, PH was associated with systemic arterial hypertension (p<0.001) and coronary artery disease (p=0.014), but not emphysema. CONCLUSIONS: In this study, fewer patients with cancer had surrogate parameters for PH compared with previously published results among patients with lung cancer. Consequently, the prevalence of PH in other cancers might be lower compared with lung cancer; however, PH still has a negative impact on prognosis. Furthermore, our data does not provide evidence that lung metastases cause PH. Thus, our results support the idea that lung cancer-associated PH represents a new category of PH. Our results also highlight the importance of further studies in the field of cardio-oncology.


Assuntos
Hipertensão Pulmonar , Neoplasias , Humanos , Hipertensão Pulmonar/mortalidade , Feminino , Masculino , Estudos Retrospectivos , Idoso , Pessoa de Meia-Idade , Neoplasias/complicações , Neoplasias/mortalidade , Prevalência , Biomarcadores/sangue , Prognóstico , Tomografia Computadorizada por Raios X , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/complicações
2.
Chirurgie (Heidelb) ; 94(7): 608-615, 2023 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-37335317

RESUMO

Acute mesenteric ischemia is a severe illness, which if untreated, rapidly leads to a critical condition with sepsis, multiple organ failure and death in affected patients. The diagnosis and initiation of treatment of acute mesenteric ischemia should be performed as early and expeditiously as possible and follows the principle of the shortest possible time to reperfusion. Otherwise, the outcome of the patient rapidly deteriorates. The treatment algorithm should be adapted to the pathogenesis of the ischemia, the clinical condition and symptoms of the patients. With clinical signs of peritonitis, intestinal gangrene must be assumed and the abdomen should be surgically explored to detect and treat possible foci of sepsis at an early stage. The treatment of acute mesenteric ischemia should always be performed by an interdisciplinary team with all surgical and interventional options for intestinal revascularization as well as comprehensive intensive care medicine according to the standards of the Intestinal Stroke Center described in the literature. A short duration to revascularization and treatment in this interdisciplinary concept improves the outcome of patients with acute mesenteric ischemia. The World Society of Emergency Surgery provides expert consensus-based recommendations for the diagnosis and treatment of acute mesenteric ischemia; however, there is still a significant lack of broad high-quality evidence for this critical illness. Recommendations of the German specialist societies are urgently needed to ensure appropriate care, from the initial diagnostics to treatment and aftercare, for patients with suspected mesenteric ischemia in this country.


Assuntos
Isquemia Mesentérica , Humanos , Isquemia Mesentérica/diagnóstico , Isquemia Mesentérica/cirurgia , Intestinos/cirurgia , Isquemia/diagnóstico , Isquemia/cirurgia , Procedimentos Cirúrgicos Vasculares/efeitos adversos , Cuidados Críticos
3.
Thorax ; 76(2): 201-204, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33177230

RESUMO

Various forms of diffuse parenchymal lung disease have been proposed as potential consequences of severe COVID­19. We describe the clinical, radiological and histological findings of patients with COVID­19-associated acute respiratory distress syndrome who later developed severe organising pneumonia including longitudinal follow-up. Our findings may have important implications for the therapeutic modalities in the late-phase of severe COVID­19 and might partially explain why a subgroup of COVID­19 patients benefits from systemic corticosteroids.


Assuntos
COVID-19/complicações , Pulmão/diagnóstico por imagem , Pneumonia/etiologia , SARS-CoV-2 , Idoso , Biópsia , COVID-19/diagnóstico , COVID-19/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Pneumonia/diagnóstico , Tomografia Computadorizada por Raios X
4.
J Cardiovasc Comput Tomogr ; 9(5): 422-7, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25939252

RESUMO

BACKGROUND: Multidetector CT (MDCT) is performed to evaluate patients before transcatheter aortic valve replacement (TAVR). MDCT can uncover relevant nonvascular incidental findings. The use of venous phase imaging (VPI) in MDCT before TAVR has not been evaluated. OBJECTIVE: To evaluate the incidence of nonvascular findings in MDCT before TAVR with effect on the TAVR procedure and the value of VPI in this setting. METHODS: Sixty-four-slice MDCT angiography with VPI (100 mL contrast agent with 370-mg iopromide per mL) in 76 patients was retrospectively evaluated by 2 readers. Nonvascular findings were separately assessed on arterial and venous phase images and categorized in consensus as nonsignificant (no effect on TAVR), intermediate (further workup or surveillance necessary, no effect on TAVR), or significant (effect on TAVR). Radiation dose was recorded as dose-length product (DLP) and effective dose was calculated. RESULTS: A total of 169 findings were detected, of which 155 (91.7%) were nonsignificant, 13 (7.7%) were intermediate, and 1 (0.6%) was significant. TAVR was canceled in 1 patient (1.3%) because of suspected pancreatic cancer. No significant finding was seen on VPI only. Mean total DLP was 1137.9 mGy·cm (16.07 mSv) and the proportional mean DLP of VPI was 403 mGy·cm (6.85 mSv). CONCLUSION: The incidence of nonvascular significant findings in MDCT before TAVR is low and VPI in our series did not add value. However, it may be considered in selected patients.


Assuntos
Estenose da Valva Aórtica/diagnóstico por imagem , Estenose da Valva Aórtica/terapia , Valva Aórtica/diagnóstico por imagem , Cateterismo Cardíaco/métodos , Angiografia Coronária/métodos , Implante de Prótese de Valva Cardíaca/métodos , Achados Incidentais , Tomografia Computadorizada Multidetectores/métodos , Interpretação de Imagem Radiográfica Assistida por Computador/métodos , Idoso , Idoso de 80 Anos ou mais , Meios de Contraste , Feminino , Humanos , Iohexol/análogos & derivados , Masculino , Valor Preditivo dos Testes , Doses de Radiação , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA